Search the Newsreel

ADCT|ADC Therapeutics SA|Price:1.050|Chg%:-0.180

ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Estimates By $0.11 EPS

ADC Therapeutics (NYSE:ADCT) announced its latest earnings, reporting a loss of $0.11 EPS, which beat the consensus estimate by $0.11. The company's revenue reached $19.25 million, also surpassing expectations. Key takeaways from the earnings call include FDA concerns about the LOTIS-5 combination therapy, progress …

ADC Therapeutics SA: Shareholders Board Members Managers and Company Profile | CH0499880968

This page provides a detailed company profile for ADC Therapeutics SA, a Switzerland-based clinical-stage oncology drug discovery and development company. It outlines the company's business description, sales by activity and geographical breakdown, executive committee, board of directors, and major shareholders. Financial data, analyst consensus, …

Earnings call transcript: ADC Therapeutics beats Q2 2026 estimates but shares fall

ADC Therapeutics (ADCT) exceeded Q2 2026 earnings and revenue estimates, but its shares fell due to regulatory concerns regarding its ZYNLONTA combination program, LOTIS-5. Despite the stock drop, the company's ZYNLONTA monotherapy sales remained stable, and management expects its cash reserves to last until …

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.5 per share a year ago. These figures are adjusted for non-recurring items. This …

ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q2 2026 Earnings

ADC Therapeutics SA (ADCT) released its Q2 2026 earnings, reporting -$0.11 per share, which beat analyst estimates. The company's revenue of $19.25 million missed estimates. The article also details recent insider trading activity, with significant sales by REDMILE GROUP, LLC, and outlines institutional investor …

ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss

ADC Therapeutics (ADCT) reported a narrowed GAAP loss per share in Q2 2026, reaching $0.11, primarily due to a significant 29% reduction in operating expenses, despite only a modest 2% increase in total revenue to $19.2 million. However, the company faces material regulatory uncertainty …

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics announced its Q2 2026 financial results, with net product revenue of $18.6 million and cash reserves of $219.1 million. The company is evaluating the regulatory path for ZYNLONTA® following FDA feedback on the LOTIS-5 trial and is considering a Phase 3 trial …

Earnings To Watch: ADC Therapeutics SA (ADCT) Q2 2026 -- GF Value Sees 125% Upside

ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview

ADC Therapeutics SA is projected to report a loss of 21 cents per share, according to an earnings preview. The article, sourced from Reuters, provides this financial expectation ahead of the company's full earnings release.

ADC Therapeutics SA (ADCT) Earnings Forecast: Future EPS & Revenue Growth Estimates

ADC Therapeutics SA (ADCT) Stock News Today

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

ADC Therapeutics (NYSE: ADCT) announced it will host a conference call and live webcast on Thursday, August 13, 2026, at 8:30 a.m. EDT to report its second-quarter 2026 financial results and provide operational updates. Interested parties can register to access the conference call or …

ADC Therapeutics' Aug. 13 Results Update Will Be Webcast Live

ADC Therapeutics (ADCT) to Post Quarterly Earnings on Tuesday

ADC Therapeutics (ADCT) is scheduled to release its Q2 2026 earnings before market open on Tuesday, August 11th. Analysts are anticipating a loss of $0.19 per share on revenues of $18.89 million. The company's stock is currently trading around $1.08, significantly below its 52-week …

ADCT|ADC Therapeutics SA|Price:1.055|Chg%:+0.005

This article provides a comprehensive stock analysis of ADC Therapeutics SA (ADCT), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation. Despite a weak stock market performance recently, the company shows strong fundamentals and institutional confidence. Analysts have rated it as a …

ADC Therapeutics SA (ADCT) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for ADC Therapeutics SA (ADCT), detailing its current risk score, industry ranking, and beta value. It presents various financial metrics including VaR, maximum drawdown, volatility, daily returns, and Sharpe Ratio over different periods. The assessment also covers liquidity …

ADC Therapeutics SA (ADCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of ADC Therapeutics SA (ADCT), detailing its current price momentum score, support and resistance levels. It includes a breakdown of various technical indicators like MACD, RSI, and moving averages, offering insights into potential buy, sell, or neutral signals. …

Orbimed Advisors LLC Has $4.94 Million Stock Position in ADC Therapeutics SA $ADCT

Orbimed Advisors LLC significantly reduced its stake in ADC Therapeutics SA (NYSE:ADCT) by 77.4% in Q1, selling 4.5 million shares but retaining 1.32 million shares valued at $4.94 million. Institutional investors collectively own 41.1% of the company, which reported a quarterly loss of $0.21 …

ADC Therapeutics SA - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It focuses on developing antibody drug conjugates (ADCs) for the treatment of various cancers, with key drug candidates ADCT-301 and ADCT-402 in clinical trials. The company's main revenue source is its …

ADC Therapeutics SA (ADCT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of the shareholder structure for ADC Therapeutics SA (ADCT), including major individual and institutional holdings. It lists the top shareholders by proportion, categorizes shareholders by type, and offers a historical view of institutional shareholding changes over several quarters. …

ADCT|ADC Therapeutics SA|Price:1.150|Chg%:-0.045

ADC Therapeutics SA (ADCT) is a Switzerland-based clinical-stage oncology company specializing in antibody drug conjugates (ADCs) for cancer treatment. Despite healthy fundamentals and high growth potential, its stock price has been trending down in the medium term, though analysts rate it as a "Buy" …

ADC Therapeutics SA (NYSE:ADCT) Receives Consensus Rating of "Hold" from Analysts

ADC Therapeutics SA (NYSE:ADCT) has received a consensus "Hold" rating from six research firms, with an average 1-year price target of $6.25. The company's stock recently traded at $1.23, down 1.1%, with a market cap of $155.9 million. Despite missing EPS expectations in its …

ADC Therapeutics stock stabilizes as Zynlonta revenue supports biotech valuation

ADC Therapeutics (ADCT) stock is stabilizing, supported by strong Zynlonta revenue growth (up 30% to $96 million in fiscal 2024), which primarily drives the company's commercial performance. Despite continued operating losses ($180 million in 2024) and high R&D spending ($130 million), the Swiss biotech …

ADC Therapeutics stock trades steady as revenue grows and liquidity plan develops

ADC Therapeutics (ADCT) is experiencing steady stock performance as its revenue grows and a liquidity plan develops. The company reported a 45.7% increase in total revenue for Q1 2024, reaching $19.4 million, driven primarily by sales of its drug Zynlonta. While still operating at …

ADC Therapeutics (NYSE:ADCT) Shares Down 6.3% - Time to Sell?

ADC Therapeutics (NYSE:ADCT) shares dropped 6.3% on Monday, trading low at $1.26 with significantly reduced volume. Analyst sentiment is mixed, with some maintaining "overweight" while others downgraded the stock, leading to a consensus "Hold" rating and an average price target of $6.25. The company …